Search Results

You are looking at 1 - 10 of 922 items for :

  • "Screening" x
Clear All
Full access

Bernardo H. L. Goulart, Mark E. Bensink, David G. Mummy and Scott D. Ramsey

disease is rarely curable. Lung cancer screening tests can potentially reduce cancer mortality through detecting tumors at earlier stages, when treatments have higher chances of cure. 2 , 3 The NCI-sponsored National Lung Screening Trial (NLST) is the

Full access

Randall W. Burt, Jamie A. Cannon, Donald S. David, Dayna S. Early, James M. Ford, Francis M. Giardiello, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Kory Jasperson, Jason B. Klapman, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman, David Weinberg, Mary Dwyer and Deborah Freedman-Cass

of -2.7% in men and -2.1% in women from 2004 to 2008. 3 In addition, mortality from CRC decreased by almost 35% from 1990 to 2007, 4 likely because of earlier diagnosis through screening and better treatment modalities. Currently, patients with

Full access

Edward E. Partridge, Nadeem R. Abu-Rustum, Susan M. Campos, Patrick J. Fahey, Michael Farmer, Rochelle L. Garcia, Anna Giuliano, Howard W. Jones III, Subodh M. Lele, Richard W. Lieberman, Stewart L. Massad, Mark A. Morgan, R. Kevin Reynolds, Helen E. Rhodes, Diljeet K. Singh, Karen Smith-McCune, Nelson Teng, Cornelia Liu Trimble, Fidel Valea and Sharon Wilczynski

women without access to health care and those who have immigrated to the United States from countries where cervical cancer screening is not routinely performed. 2 Because cervical cytology screening is the current method for early detection of this

Full access

Douglas Arenberg and Ella A. Kazerooni

In November 2010, the National Lung Cancer Screening Trial (NLST) was halted by the NIH, with the compelling news that CT reduced lung cancer mortality by 20% and all-cause mortality by 7% when 3 annual low-dose helical CT scans were performed in

Full access

Douglas E. Wood, Ella A. Kazerooni, Scott L. Baum, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Inga T. Lennes, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Peter Mazzone, Robert E. Merritt, Bryan F. Meyers, David E. Midthun, Sudhakar Pipavath, Christie Pratt, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Mark L. Schiebler, Betty C. Tong, William D. Travis, Benjamin Wei, Stephen C. Yang, Kristina M. Gregory and Miranda Hughes

these symptoms usually have advanced lung cancer. These facts—combined with the success of cervical, colon, and breast cancer screening—have been the impetus for developing an effective lung cancer screening (LCS) test. 8 – 10 Ideally, effective

Full access

Therese B. Bevers, Mark Helvie, Ermelinda Bonaccio, Kristine E. Calhoun, Mary B. Daly, William B. Farrar, Judy E. Garber, Richard Gray, Caprice C. Greenberg, Rachel Greenup, Nora M. Hansen, Randall E. Harris, Alexandra S. Heerdt, Teresa Helsten, Linda Hodgkiss, Tamarya L. Hoyt, John G. Huff, Lisa Jacobs, Constance Dobbins Lehman, Barbara Monsees, Bethany L. Niell, Catherine C. Parker, Mark Pearlman, Liane Philpotts, Laura B. Shepardson, Mary Lou Smith, Matthew Stein, Lusine Tumyan, Cheryl Williams, Mary Anne Bergman and Rashmi Kumar

This decrease has been attributed to mammographic screening and treatment advances. 5 Diagnostic Evaluation Breast symptoms are common among women. A retrospective study of women aged 40 to 70 years showed that 16% (total visits of 23 per 100

Full access

Jennifer A. Lewis, Heidi Chen, Kathryn E. Weaver, Lucy B. Spalluto, Kim L. Sandler, Leora Horn, Robert S. Dittus, Pierre P. Massion, Christianne L. Roumie and Hilary A. Tindle

5-year survival of only 18%. 1 Low-dose CT (LDCT) can detect early-stage lung cancer, increasing the likelihood of cure. The National Lung Screening Trial (NLST), a large, multicenter, US randomized controlled trial, was terminated early when it

Full access

Omar Abdel-Rahman

Background Cancer screening programs represent a pivotal component of all cancer care programs among different Canadian jurisdictions. 1 Previously published evidence has shown that targeted screening for some solid tumors is associated with

Full access

Douglas E. Wood, George A. Eapen, David S. Ettinger, Lifang Hou, David Jackman, Ella Kazerooni, Donald Klippenstein, Rudy P. Lackner, Lorriana Leard, Ann N. C. Leung, Pierre P. Massion, Bryan F. Meyers, Reginald F. Munden, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Michael Unger and Stephen C. Yang

-year survival rates for lung cancer are only approximately 15.6%, partly because most patients have advanced-stage lung cancer at initial diagnosis ( http://seer.cancer.gov/statfacts/html/lungb.html ). 5 These facts, combined with the success of screening in

Full access

Sean Dineen, Patrick M. Lynch, Miguel A. Rodriguez-Bigas, Sarah Bannon, Melissa Taggart, Colleen Reeves, Cathy Modaro, Michael Overman, George J. Chang, John M. Skibber and Y. Nancy You

analytic models. 8 , 13 , 14 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CRC Screening have evolved to place increasing emphasis on molecular testing for detection of hereditary cancer syndromes, specifically testing for MMR